UPDATED Monday, April 26, 2021, 9:00 a.m. EDT—President Biden signed the two bills into law on April 23.
The U.S. House of Representatives passed two bills last week intended to reduce the overall costs of medications by boosting competition for generic drugs and biosimilars. As both bills were previously passed by the Senate, they are headed to President Joe Biden’s desk for his signature.
The U.S. House of Representatives passed two bills last week intended to reduce the overall costs of medications by boosting competition for generic drugs and biosimilars. As both bills were previously passed by the Senate, they are headed to President Joe Biden’s desk for his signature.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
